The Discovery of Abl Kinase ATPase Activity and Its Implications in the Development of Straightforward Assays

Abelson kinase (Abl) is an enzyme crucial in metabolic pathways, and it is a molecular target for leukemias, especially chronic myeloid leukemia. Despite extensive research on its kinase function and inhibition over the years, there is still considerable room for new discoveries regarding its mechanistic and reactive aspects. We report here, for the first time, the intrinsic ATPase activity of Abl in the absence of peptide substrates. Using quantitative one-dimensional <sup>31</sup>P nuclear magnetic resonance spectroscopy, we monitored the conversion of ATP to ADP and inorganic phosphate (Pi) catalyzed by Abl. Furthermore, we demonstrated that the known kinase inhibitors imatinib and dasatinib inhibit ATPase activity. Beyond expanding the biochemical repertoire of Abl, this finding enables a straightforward, substrate-free assay for kinase inhibition, offering new perspectives on kinase catalytic plasticity and laying the groundwork for simplified screening strategies in drug discovery.

Authors

Institutions

Publication Details

Journal
ACS Omega
Published
2025-11-12
DOI
https://doi.org/10.1021/acsomega.5c08176
Citations
1
Primary Topic
Chronic Myeloid Leukemia Treatments
Type
article
Field-Weighted Citation Impact
1.77
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The Discovery of Abl Kinase ATPase Activity and Its Implications in the Development of Straightforward Assays

Adolfo H. Moraes, Tiago Brandão, Diego Martins, Philipe Oliveira Fernandes et al.
1 citations
ACS Omega
Chronic Myeloid Leukemia Treatments
1.77
article

The Discovery of Abl Kinase ATPase Activity and Its Implications in the Development of Straightforward Assays

Adolfo H. Moraes, Tiago Brandão, Diego Martins, Philipe Oliveira Fernandes, Lucas A. Vieira
article en
1 citations

Abstract

Abelson kinase (Abl) is an enzyme crucial in metabolic pathways, and it is a molecular target for leukemias, especially chronic myeloid leukemia. Despite extensive research on its kinase function and inhibition over the years, there is still considerable room for new discoveries regarding its mechanistic and reactive aspects. We report here, for the first time, the intrinsic ATPase activity of Abl in the absence of peptide substrates. Using quantitative one-dimensional <sup>31</sup>P nuclear magnetic resonance spectroscopy, we monitored the conversion of ATP to ADP and inorganic phosphate (Pi) catalyzed by Abl. Furthermore, we demonstrated that the known kinase inhibitors imatinib and dasatinib inhibit ATPase activity. Beyond expanding the biochemical repertoire of Abl, this finding enables a straightforward, substrate-free assay for kinase inhibition, offering new perspectives on kinase catalytic plasticity and laying the groundwork for simplified screening strategies in drug discovery.

ACS OmegaVol. 10(46)
Universidade Federal de Minas Gerais (BR), Instituto de Investigaciones en Ciencias de la Salud (AR), Instituto de Ciências Farmacêuticas (BR), Resonance Research (United States) (US)
Openalex Percentile: Top 11%
Chronic Myeloid Leukemia Treatments
1.77
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.